Ritonavir-13C3
Ritonavir-13C3 is 13C labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM.
For research use only. We do not sell to patients.
- CAS No.: 1217673-23-8
- Formula: C3413C3H48N6O5S2
- Molecular Weight:723.92
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 1217673-23-8
-
Unlabeled Cas 155213-67-5
-
Molecular Weight 723.92
-
Formula C3413C3H48N6O5S2
-
SMILES
CN(C(N[C@@H](C(C)C)C(N[C@H](C[C@@H]([C@@H](NC(O[13CH2][13C]1=[13CH]N=CS1)=O)CC2=CC=CC=C2)O)CC3=CC=CC=C3)=O)=O)CC4=CSC(C(C)C)=N4
-
Synonyms
ABT 538-13C3; RTV-13C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
DMSO : 25 mg/mL (34.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
References
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
[2]. Kumar GN, et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos. 1999 Aug;27(8):902-8. [Content Brief]
[3]. Eagling VA, et al. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol. 1997 Aug;44(2):190-4. [Content Brief]
[4]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212. [Content Brief]
[5]. Weichold FF, et al. HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. J Hum Virol. 1999 Sep-Oct;2(5):261-9. [Content Brief]
[6]. Drewe J, et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol. 1999 May 15;57(10):1147-52. [Content Brief]
[7]. Kumar GN, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther. 1996 Apr;277(1):423-31. [Content Brief]
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.3814 mL | 6.9068 mL | 13.8137 mL | 34.5342 mL |
| 5 mM | 0.2763 mL | 1.3814 mL | 2.7627 mL | 6.9068 mL | |
| 10 mM | 0.1381 mL | 0.6907 mL | 1.3814 mL | 3.4534 mL | |
| 15 mM | 0.0921 mL | 0.4605 mL | 0.9209 mL | 2.3023 mL | |
| 20 mM | 0.0691 mL | 0.3453 mL | 0.6907 mL | 1.7267 mL | |
| 25 mM | 0.0553 mL | 0.2763 mL | 0.5525 mL | 1.3814 mL | |
| 30 mM | 0.0460 mL | 0.2302 mL | 0.4605 mL | 1.1511 mL |
Ritonavir-13C3 Related Classifications
HY-W653853 Related Classifications
Powered by Bioz